Press releases
-
-
-
-
-
Internal link ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
-
Internal link ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
-
-
Internal link ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
-
-
-
Internal link ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
-
-
-
Internal link ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
-
Internal link ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
-
-
-
-
Internal link ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
-
Internal link ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
-
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index
-
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10
-
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10
-
-
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10